Literature DB >> 23728951

Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma.

Robert W Frank1, Laura Middleton, Brendan C Stack, Horace J Spencer, Ann T Riggs, Donald L Bodenner.   

Abstract

BACKGROUND: The purpose of this study was to demonstrate a role for observation of patients with differentiated thyroid cancer (DTC) with persistent, nonlocalizable disease.
METHODS: Our study was conducted on outpatients seen at our institution from 1999 to 2009 having total thyroidectomy, radioactive iodine (RAI) ablation, measurable serum thyroglobulin (Tg), and no evidence of disease on whole body or positron emission tomography (PET) scans.
RESULTS: Nineteen patients in our study group aged 20 to 73 with an average follow-up of 5.5 years (range, 2-12 years); all were treated with postoperative RAI (99-210 mCi, average 119). Mean Tg ranged from 0.41 to 4.34. Tg levels remained stable or gradually decreased in all patients.
CONCLUSION: After total thyroidectomy and RAI therapy, patients may present with mildly elevated Tg values without localizable disease. These patients may have additional RAI treatments based on the Tg elevation. However, our clinical experience has shown that many of these patients will have Tg levels that either achieve stability or decrease over time without further treatment.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  FDG-PET; radioiodine imaging; thyroglobulin; thyroid carcinoma; ultrasound

Mesh:

Substances:

Year:  2013        PMID: 23728951     DOI: 10.1002/hed.23272

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

Review 1.  Persistent Elevation of Thyroglobulin in Patient Treated for Differentiated Thyroid Cancer: A Ten-Year Review.

Authors:  Sarah Khan; Roopashree Prabhushankar; Emily Leary; Uzma Z Khan
Journal:  Mo Med       Date:  2017 Sep-Oct

Review 2.  The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer.

Authors:  Sha Li; Chutong Ren; Yi Gong; Fei Ye; Yulong Tang; Jiangyue Xu; Can Guo; Jiangsheng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.